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INTRODUCTION 
 Hepatitis  C virus(HCV)   infects 20-50% of chronic kidney disease 
patients(47). The  number of chronic kidney  disease patients is on increasing 
trend . The number of chronic kidney disease patients undergoing  dialysis 
is also increasing. Various studies have shown that 3.4-43%  of chronic 
kidney disease patients undergoing maintenance hemodialysis test positive 
for anti HCV antibodies (48).  
 
 Hepatitis C virus infection confers 1.62-2.39  fold  increase in risk  of  
death for hemodialysis patients (49). 
 
 Various studies have shown that quality of life, morbidity and 
mortality of  chronic kidney disease patients on maintenance hemodialysis 
is worse when compared to the quality of  life, morbidity and mortality of 
patients undergoing renal transplantation. For these reasons, renal 
transplantation is better therapeutic option for hepatitis C virus infected 
patients on maintenance hemodialysis. Anti viral therapy for hepatitis C 
virus should be given before transplantation. The recommendation is to 
screen for hepatitis C virus infected  patients on transplant programme by 
testing antibodies for hepatitis C virus.  
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 If antibodies to hepatitis C virus is detected, we should proceed 
testing  hepatitis C virus RNA . If hepatitis C Virus RNA is detected, 
genotyping should be done. Based on the genotype , interferon should be 
given before transplant. Patients attaining sustained viral response after 
interferon therapy should be taken for renal transplant, after ruling out 
clinical and biochemical evidence of liver cirrhosis. 
 Most of the available studies has shown that the patient and graft 
survival is worse in hepatitis C virus infected recipients when compared 
with hepatitis C uninfected recipients. The incidence of acute rejection , new 
onset of diabetes mellitus after transplant(NODAT),sepsis, interstitial 
fibrosis and tubular atrophy , progression of liver disease  is higher in  
hepatitis C virus infected recipients when compared with hepatitis C 
uninfected recipients. Hepatitis C virus infected recipients are also at risk of 
developing glomerular diseases like membrano proliferative 
glomerulonephritis with or without cryoglobulinemia , membranous  
glomerulonephritis, thrombotic microangiopathy.  
 After transplant, interferon given increases the immunogenicity of the 
graft    leading to graft loss. The only indications for giving interferon post 
transplant are fibrosing  cholestasis and life threatening vasculitis. 
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AIMS AND OBJECTIVES 
 
AIM  OF THE STUDY 
 To study of clinical outcomes of renal transplantation in hepatitis C  
virus positive renal transplantation recipients .         
    
PRIMARY OBJECTIVES 
 To assessing the  all cause mortality among hepatitis c virus positive 
recipients. 
 
SECONDARY OBJECTIVE 
1. Graft dysfunction 
2. Acute rejection  
3. New onset  of diabetes mellitus  
4. Sepsis and associated infections. 
5. Proteinuria  
6. Interstitial fibrosis and tubular atrophy. 
7. Liver cell failure.  
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METHODOLOGY 
STUDY POPULATION 
 Patients on live related and cadaver transplantation programme were 
screened for Hepatitis C virus by anti HCV antibody testing and qualitative 
HCV  RNA load, patients who were found to be positive for hepatitis c virus 
and underwent either live related or cadaver transplantation in our 
department  during  2010 -2013  were followed in our ward and out  patient 
department. 
 
INCLUSION CRITERIA 
 Patients who were found to have hepatitis C virus positive patients 
who underwent either live related or cadaver transplantation in our 
department. 
 
EXCLUSION CRITERIA 
 Pre transplant liver cirrhosis  
 Pre transplant diabetes mellitus 
 Hepatitis  B virus positive  renal failure patients. 
 
STUDY DESIGN 
 Single Arm Retrospective and Prospective Observational study. 
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SUBJECTS AND METHODS 
 Patients who were eligible for either live related or cadaver renal 
transplant during their pre transplant work up were screened for diabetes 
mellitus  by blood sugar testing; liver cirrhosis by liver function test, 
ultrasound, portal doppler, upper gastro intestinal endoscopy; hepatitis c 
virus by anti h c v antibody testing and qualitative hepatitis C  RNA viral 
load, Hepatitis B virus by HBsAg. 
 
 Patients who were found to have hepatitis c virus positive  and not 
having diabetes mellitus, clinical liver cirrhosis  undergoing either live 
related or cadaver renal transplantation  were included in my study. 
 
DEFINITIONS USED 
SUSTAINED VIRAL RESPONSE: 
 After treatment with interferon  RNA levels should be  < 50  iu /ml 
for six months.  
 
DELAYED GRAFT FUNCTION:  
 Requirement of hemodialysis within seven days of transplantation. 
 
 POST TRANSPLANT LIVER DYSFUNCTION:  
 Depending  on the degree of elevation of liver enzymes ( aspartate 
aminotransferae and alanine aminotransferase) 
 
6 
 
MILD CHRONIC LIVER DYSFUNCTION(> 6 MONTHS) 
 Rise in liver enzymes upto  two and half  times the normal levels. 
 
MODERATE CHRONIC LIVER DYSFUNCTION (>6MONTHS) 
 Elevation in liver enzymes  more than two and half times the normal 
levels.  
 
ACUTE HEPATITIS (> 7 DAYS <6MONTHS) 
 Elevation in   liver enzymes  more than two and half times of normal . 
 
DECOMPENSATED CHRONIC LIVER DISEASE : 
 Occurrence of one clinical jaundice, fluid in the abdomen, 
encephalopathy due to liver pathology, bleeding from the varices in the 
gastro intestinal tract . 
 
NEW ONSET OF  DIABETES  MELLITUS  AFTER  TRANSPLANT 
(NODAT): 
 Patients with no history of diabetes mellitus or treatment for diabetes 
mellitus  undergoing  transplantation and developing diabetes mellitus after 
transplant  requiring treatment.  
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STATISTICAL ANALYSIS  
 Data analysed with SPSS software version 16.0 for  windows.  All 
continuous data  expressed as mean +/-  standard deviation  . Continuous 
data analysed using  unpaired t test. Categorical data  expressed as number 
(percentage) . Fishers exact test were used to analyze the categorical data. A  
p value  of <0.05  is significant statistically.  
 
 Univariate  analysis  done to evaluate odds ratio with confidence 
interval and relative risk of various parameters that  increases the risk of 
HCV infection among  recipients. 
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REVIEW OF LITERATURE 
 
 Hepatitis C virus (HCV) is a RNA virus. This virus belongs  to 
flaviviridae  family. The  RNA  genome of HCV is single stranded and 
positive stranded. Its length is 9.6 kb with a single open reading frame. It 
encodes a single polyprotein precursor of approximately 3000 residues 
which are flanked on both sides by untranslated regions (1).  
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 Ten different proteins are produced upon cleavage of precursor 
polyprotein.   It includes 4 structural proteins which includes core protein, 
envelope protein (E1), envelope protein 2(E2), small polypeptide  
protein(p7) and 6 non structural protein-non structural protein 
(NS2,NS3,NS4A,NS4B, NS5A and NS5B). 
 
 Genetic variability is a characteristic feature of HCV genome, it is of 
high degree. Mutation rates of various regions in the viral genome is 
variable. The most variable regions are envelope E1 and E2. The viral 
genome sequence are highly conserved in the 5’ UTR and terminal segment 
of 3’ UTR. The imperfect proof reading of the viral RNA dependent RNA 
polymerase  accounts for this high degree of mutation rate. This causes co 
existence of different mutants of the parent strain as quasispecies (2).  
 
 As cell cultures for HCV are not present, studies of infectivity have 
come from chimpanzee. When chimpanzees are exposed to hepatitis C 
virus, HCV RNA appears in the serum within 1-2 weeks, followed by 
elevation of serum alanine amino transferase 3-6 weeks, followed by 
development of antibodies against HCV core  NS3  and NS4. 
 
EPIDEMIOLOGY  
 The strains from different  geographical  regions have large 
differences in the HCV genome . This leads  to classification into six major 
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genotypes. The commonest  genotype throughout the world are type 1,2 and 
3. The commonest   genotype in  north  africa and middle east is type 4. The 
commonest  genotype in south  Africa  is  type  5 . The  commonest  
genotype  in   south east asia is type 6. (3)(4) 
 
 The classification of HCV into various genotypes is a major predictor 
of anti viral treatment response.  Genotype 1 has a poorer response to 
treatment with interferon and progression of severe chronic hepatitis. It 
neither has an impact on clinical presentation of the disease nor the severity 
of the disease.  
 
 In northern, eastern and western  india  genotype 3 is common .In 
southern india genotype 1 is common. 
 
Proportion of various  genotypes in India 
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 Studies from North india –N; West india –W; East india –E; South 
and east india –S&E ; South india-S; Throughout india AII (5). 
 
 World wide there is varied prevalence of hepatitis c virus infection in 
chronic kidney disease patients undergoing dialysis, ranging from less than 
one percent to more than seventy percent. 
 
 In chronic kidney disease patients in hemodialysis the prevalence of  
infection with HCV  is 12- 42% in India (6). 
 
 HCV  infection prevalence can vary between each dialysis unit within 
a country. The important  factors that confers increased  for HCV  infection 
include blood transfusions without proper screening for hepatitis c virus, 
duration of dialysis and change in  the number of dialysis centers . 
 
LABORATORY DIAGNOSIS OF H C V 
HCV is diagnosed by three following methods : 
1. Testing serology for  antibodies against hepatitis c virus antigens. 
2. Test to detect and quantify hepatitis c virus antigens. 
3. Test that  detects and quantifies  hepatitis c virus genomes .Test that 
sequences  the HCV  genome. 
 
 Tests that are routinely used to screen and diagnose hepatitis C virus  
infection are serologic and bio–molecular based . 
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 Serological tests include enzyme immunoassay (EIA), recombinant 
immunoblot assay (RIBA) and tests to detect specific genotype antibodies. 
 
Molecular tests are, 
• Quantitative tests which detects hepatitis C virus RNA,   
• Quantitative tests which measures the load of  H C V- index for  
replication of HCV 
• Test which sequence the hepatitis c virus genome (7). 
 
HCV RNA DETECTION AND QUANTIFICATION 
QUALITATIVE HCV RNA TESTS 
 These   tests  uses  target  amplification  principle. Qualitative HCV 
RNA tests are done either by polymerase chain reaction or  by  target 
mediated amplification methods. 
 
QUANTITATIVE HCV RNA TESTS 
 By using the methods that amplifies the target ( polymerase chain 
reaction either conventional or real time) and  methods that amplify the 
signal (branched DNA) HCV RNA is quantified. 
 
INTERPERATION OF TESTS: 
 Chronic kidney disease patients on hemodialysis will have a lower 
transaminase levels when compared to individuals with normal renal 
function. Normal transaminases levels have been documented in 25% of 
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patients with HCV infection. HCV infection should be suspected whenever 
there is elevation of transaminase (8). After  1-2 weeks of exposure to 
hepatitis c virus only, HCV RNA is detected. 
 
 After 8 weeks of hepatitis c virus exposure, anti HCV antibodies are 
detected. So, we can’t exclude HCV infection by a negative anti HCV  
test (9).  
 
 The detection of hepatitis c virus antibodies by serological tests 
implies that the patient is having acute or chronic infection, but these tests 
cannot discriminate acute infection from chronic or resolved infection.   
 
 In about 50-93% of the patients with acute hepatitis c virus infection 
and 50-93% of chronic hepatitis c virus infection , anti hepatitis c virus IgM 
antibodies cannot be detected, which implies that in diagnosing acute 
infection these serological tests are not a reliable indicator. 
 
 In low risk patients (healthy blood donors) and in high risk patients 
who are negative for hepatitis c virus RNA, recombinant immunoblot assay 
(RIBA) is needed. For patients with indeterminate RIBA results  , sensitive 
tests which detect hepatitis C virus RNA should be done. 
 
 Qualitative RNA tests should be done in patients with acute hepatitis 
of uncertain orgin and patients whose tests for serology is negative. 
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 HCV RNA tests are also used in few immunocompromised patients, 
in hemodialysis patients and in mixed cyroglobulemic patients who test  
false negative on serology. 
 
HEPATITIS C VIRUS AND KIDNEY 
 HCV causes various glomerular lesions, especially membrano 
proliferative glomerular lesions associated with or without 
cryoglobulinemia, focal segmental glomerulosclerosis and membranous 
glomerulonephritis. In diabetic chronic kidney disease patients, HCV  
infection causes the   glomerular filtration rate  tom decline rapidly (10). 
 
 Chronic kidney disease patients on hemodialysis, have higher 
prevalence of infection of hepatitis C virus when compared to general 
population. These patients are also associated with increased mortality 
rate(11).  
 
PREVALANCE OF HCV INFECTION IN  CKD 
 Worldwide the prevalence of HCV infection  in chronic hemo 
dialysis, ranging from less than one percent to more than seventy percent. 
 
 According to the study by Saha  D and SK Agarwal in India the HCV 
prevalence was 12-42% in 2001(12). 
 
15 
 
 The prevalence of hepatitis C virus can vary between each dialysis 
unit within a country. 
 
 The notable  factors that increases the risk  for hepatitis C virus 
infection are   blood transfusion without proper screening for HCV ,use of   
intravenous drugs , duration of dialysis ,number of dialysis centers  patient 
underwent dialysis, patient undergoing dialysis in a dialysis center with high 
prevalence of Hepatitis C virus, history of renal transplantation. 
 
TRANSPLANTATION IS A BETTER OPTION THAN DIALYSIS 
 When comparing the dialysis patients infected with hepatitis C virus , 
renal transplantation is   a  better outcome. The evidence for this better 
outcome comes from three studies. 
 
 The study by BRAIN J.G. PEREIRA et al, states the beneficial rather 
than adverse effect of renal transplantation on long term survival in anti 
HCV  positive patients when compared to  HCV infected  patients on 
dialysis(13). 
Study  by KNOLL et al,  concludes that the survival of HCV infected 
patients on dialysis is decreased when compared to hepatitis C virus infected  
renal transplanted recipients.(14). 
 
 Study by BLOOM et al, retrospectively compared 138 renal 
transplant HCV virus positive recipients with 177 HCV  positive dialysis 
16 
 
patients, renal transplant wait listed patients. The mortality of transplanted 
recipients was approximately 20 % and mortality of hepatitis c virus 
positive patients was approximately 50%, with p =0.003(15). 
 
TREATMENT  FOR HEPATITIS C VIRUS 
INTERFERON ALFA 
 This parenteral drug acts by binding  to specific membrane receptors 
on cell surface. It acts by suppressing  the proliferation of virus infected   
cells, modulating  the immune activity of host cells, inhibition of replication 
of virus. 
 
PEG  INTERFERON  ALFA 
 These agents have polyethyelene glycol moiety attached by  a 
covalent bond. This modification prolongs the terminal half life and slows 
the clearance . 
 
RIBAVIRIN 
 This anti viral agent is a gaunosine analog, enzymes present in the 
host phosphorylates intracellularly.  
 
 It exerts it anti viral property by interfering the synthesis of guanosine 
triphosphate, causes inhibition of viral m RNA capping. It also inhibits 
RNA dependent RNA polymerase. 
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TELAPREVIR , BOCEPREVIR 
 These drugs act by inhibiting non structural protease NS 3/ NS 4A 
 
MIRAVIRSEN  
 Inhibits microRNA expressed in the liver  miR122, thereby the 
replication of hepatitis c virus. 
 
 Of these anti viral drugs, only interferon  and ribavarin  are used in 
clinical practise in treating hepatitis c virus.  
 
 Ribavarin is not used in chronic kidney  disease as it causes 
haemolytic anaemia. 
 
MANAGEMENT OF CKD PATIENTS INFECTED WITH 
HEPATITIS C VIRUS  
 As  hepatitis C virus causes various immune complex mediated 
glomerulonephritis and has  an adverse impact on survival of patients on 
maintenance hemodialysis, it is very important to treat hepatitis C virus 
HCV infection. The survival of  hepatitis C virus  infected renal transplant 
recipients is inferior when compared to renal transplant recipients not 
infected with hepatitis c virus. The chances of occurrence of de novo 
glomerulonephritis of the allograft and NODAT is very high. 
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 Thus, it is very important to treat chronic kidney disease patients 
infected with hepatitis C virus, as it clears the viremia and attainment of 
sustained viral response. 
 
 The important factors  that influences  the treatment of  CKD patients  
infected with HCV  are histology of the liver, patient age, associated co 
morbidities and the tolerance of patient to anti viral therapy.   
 
 Therapy for HCV infection in CKD patients (16).  
 
 The National institute of health (NIH) revised their consensus 
statement from 2002, suggesting that in all hepatitis c virus infected patients 
liver biopsy is not mandatory before starting anti viral therapy. 
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 Liver biopsy should be done  for genotypes 1 and 4 .  Liver biopsy is 
not recommended or genotypes 2 and 3, . Patients with chronic hepatitis  
with significant fibrosis  due to HCV i.e., Metavir score of 2 or more than 2, 
Ishak scoreof 3 or more than 3) should receive antiviral therapy. 
 
 Kdigo guidelines  states that hepatitis c virus infected chronic kidney 
disease patient showing persistent positivity to virus should undergo liver 
biopsy. 
 
 This pre transplant liver biopsy is useful in assessing the severity of 
injury to the liver and predicting the prognosis and  pre transplant and post 
transplant management.  
 
HISTOLOGICAL SCORING SYSTEM OF LIVER FIBROSIS 
 
 
Adapted from Strader et al (17) 
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 Chronic kidney disease patients can acquire HCV infection by 
infected blood products transfusion or in  hemodialysis unit by hospital 
related transfusion. 
 
 As  rate of spontaneous clearance after acute HCV Infection is very 
low, when compared to general population acquiring acute HCV infection, 
treatment with antivirals  should be started. 
 
CKD Stage 5 hemodialysis diagnostic algorithm(18). 
 
  The long term survival of patient and graft of renal transplant 
recipients with HCV infection is reduced when compared with uninfected 
renal transplanted recipients. 
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 These recipients can develop acute glomerulopathy, de novo hcv 
associated nephropathy , new onset of diabetes mellitus after transplantation 
and severe sepsis. The incidence of chronic allograft nephropathy is 
increased  for these complications, it is very important HCV  infected 
patients planned for renal transplantation. 
 
  The current recommendation is that, for these  HCV  infected 
patients ant viral therapy should be given even for lesser degree of liver 
fibrosis( metavir <2 and ishak >3).  
 
 When compared to non HCV infected renal transplant recipients , 
HCV infected renal transplant recipients have poor patient and graft 
survival. This is due to the development of hepatic and extra hepatitic 
complications by hepatitis c virus (19). 
 
 In 40% of the CKD stage V patients on dialysis  patients treated with 
non pegylated interferon, sustained viral response is attained (20). 
 
 The renal transplant  recipients who achieve sustained viral response 
before transplantation with interferon therapy, the response is sustained in 
80-90% of the recipients after transplant (21). 
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 When HCV positive recipients are started on interferon after renal 
transplantation, there is high chance of graft failure and dysfunction. 
Interferon  increases the antigenicity of the allograft, by increasing the 
human leukocyte antigen (HLA) class I and II. Interferon decreases the 
function of suppressor T cells and increases the cytolytic effector immune 
cell numbers.  
 
 Acute rejection caused by interferon therapy can lead to higher 
incidence of dropouts during antiviral therapy, which is frequently steroid 
resistant and irreversible. 
 
PRE TRANSPLANTATION EVALUATION OF HEPATITIS C 
VIRUS INFECTED PATIENTS 
 Patients on live related transplant programme or on deceased donor 
programme should be initially be tested for anti  HCV anti bodies by 
enzyme immunoassay(EIA). Patients who demonstrate detectable anti HCV 
antibodies should undergo nucleic acid testing (NAT) qualitative or 
quantitative HCV RNA testing.  Patients whose HCV RNA  are 
demonstrated by nucleic acid test should undergo genotype testing.  
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PRE TRANSPLANT EVALUATION OF HEPATITIS C VIRUS 
INFECTION (22) 
EIA: enzyme immunoassay; NAT: nucleic acid test ; 
Early viral Response: patients have a  more than  2 log decrease in viral 
titer.;  IFN: interferon;  
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MANAGEMENT OF THE WAIT-LISTED PRETRANSPLANT 
CANDIDATE. (23) 
NAT: nucleic acid test; 
 EIA: enzyme immunoassay;  
SVR: sustained virologic response 
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IMMUNOSUPRESSON REGIMENS 
 Various immunosuppressive agents used during and  after renal 
transplantation has an influence over the kinetics of hepatitis c virus , 
resulting in differing effects on the replication of virus, progression of the 
liver disease, various extra hepatic manifestations and the outcomes of the 
patient and graft. 
 
 All current conventional maintenance immunosuppressive agents can 
be used in renal transplant recipients infected with hepatitis c virus. 
 
 Studies have shown that corticosteroid pulses given for acute 
rejection in HCV infected liver transplanted  recipients  leads to 100 fold 
increase in RNA levels , increased episodes of acute hepatitis and earlier 
occurrence of  recurrence of disease. 
 
ANTI VIRAL PROPERTIES OF CYCLOSPORINE 
 Cyclosprine  exerts the anti viral property by inhibiting  Cyclophilin 
B, which is a cofactor for replication of HCV genome in cells. Cyclosporine 
inhibits the association of cyclophilin B with non structural protein NS5B, 
thereby suppressing the replication of HCV genome(24).  
 
 The risk of developing nodat is very high with tacrolimus when 
compared to cyclosporine, it is advisable to follow cyclosporine based 
regimen. 
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 Mycophenoloate mofetil has being shown to infect hepatitis C virus 
replication ,but this is proven only in patients not undergoing renal 
transplantation only. 
 
 Management of hepatitis C virus related complications in kidney. 
There is no much difference in short term patient survival of hepatitis C 
virus  positive renal transplant  recipients. The proposed recommendations 
in monitoring the occurrence of any liver disease are Monitoring of liver 
enzymes after renal transplantation monthly  for the first six months and  
then every three months. 
 
 Patients with elevation of liver enzymes should be referred 
immediately to the hepatologist . Liver biopsy should be performed when 
the liver disease is worsening. Patients with liver biopsy proven cirrhosis 
should be screened by ultrasound of the liver and alfa feta protein annually 
to rule out hepatocellular carcinoma. 
 
 Management of kidney diseases associated with hepatitis c virus 
infection. Hepatitis c virus infection can cause various glomerular 
lesions,even in the absence of significant liver disease  and all patients are 
associated with HCV RNA seropositivity.  The various  renal involvement 
due to HCV infection post renal transplant are   
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• Type I membrano proliferative glomerulo nephritis associated with  
cryoglobulinemia  
• Membrano proliferative glomerulo nephritis not associated with 
cryoglobulinemia 
• Membranous glomerulonephritis 
• Focal segmental glomerlosclerosis  
• Rapidly progressive renal failure 
• Thrombotic microangioathy associated with anti cardiolipin 
antibodies  
• Fibrillary and immunotactoid glomerulopathy. 
 
 The hepatitis C virus  positive renal transplant recipients developing 
these glomerular disease  present with protienuria and microscopic 
hematuria and variable impairment of renal function. 
 
 In patients with membrano proliferative glomerluonephritis, a very 
low levels of cryoglobulins  ( cryokit levels < 3%) containing HCV RNA 
van be found in 50 % of the patients .when these recipients develop this 
glomerular involvement , they have acute nephritic syndrome in 25% and 
nephrotic syndrome in 20% of patients, they also present with hematuria 
and variable degrees of renal impairment. 
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 Renal biopsy done for these patients with cryoglobulemic membrano 
proliferative glomerulonephritis demonstrates glomerular immune complex 
deposition and other findings suggestive of  membrano proliferative 
glomerulonephritis. 
 
 The specific renal biopsy finding include precipitation of immune 
complexes or cryoglobulins  as eosinophilic material, vasculitis of small and 
medium sized renal arteries. 
 
 Electron microscopy reveals, usually a sub endothelial immune 
complex deposition and cryoglobulins deposited in fibrillar or 
immunotactoid pattern. 
 
 The clinical profile of  HCV positive renal transplant recipients 
developing non cryoglobulinemic membrano proliferative 
glomerulonephritis is similar to that of idiopathic type I membrano 
proliferative pattern.   
 
 In about 80% of hepatitis c virus  positive renal transplant recipients, 
cryoglobulinemia is detected , a higher incidence compared to 40-50% of 
non renal transplant hepatitis c virus positive patients (25). 
 
 The type of cryoglobulinemia is type III 78 %, type II is 22 %(26).  
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 Immunosuppressants given post transplant promotes the viremia of 
hepatitis C  virus  to a greater extent and alters the T helper cells 2/ T helper 
cells 1 balance towards  T helper cells 2 response , thus causing 
cryoglobulinemia. 
 
          Immune complexes containing hepatitis C virus proteins has been 
implicated in the pathogenesis of membrano proliferative glomerulo 
nephritis. 
 
 There is activation of mesangial toll like receptor 3 by immune 
complexes containing  HCV RNA . This activated immune complexes 
causes the release of various cytokines and chemokines , which affects the 
proliferation and apoptosis of mesangial cells(27).   
 
 Interferon given post transplant increase the risk of development of 
acute humoral rejection, thus complicating the treatment of  membranous 
nephropathy developing post transplant(28). 
 
 Interferon  increases the antigenicity of the allograft, by increasing 
the human leukocyte antigen (HLA) class I and II. Interferon decreases the 
function of suppressor T cells and increases the cytolytic effector immune 
cell numbers. 
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 In 50-100% of interferon treated renal transplant recipients , risk of 
developing rejection is increased(29). 
 
 The only indications were interferon can be given post transplant are 
fibrosing cholestasis and life threatening vasculitis. 
 
 Ribavarin reduces the viral load and decreases the formation of 
immune complexes . But ,ribavarin increases the viral load and worsens the 
liver function when given in the absence of antiviral therapy. 
 
 Rituximab  improves the renal function and decreases the 
cryoglobulinemia when given to hepatitis c virus positive renal transplant 
recipients(30)(31).  
 
 The recommendation is to screen for for protienuria, hematuria and 
estimated glomerular filtration rate annually to diagnose renal diseases 
caused by hepatitis C virus. 
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NEW ONSET OF DIABETES MELLITUS AFTER RENAL  
TRANSPLANTATION(NODAT) 
 Hepatitis c virus has  been implicated in the causation of new onset of 
diabetes mellitus after renal transplantation. This occurs in the early period  
after transplant. The exact pathogenic mechanism for  this development  is 
incompletely understood . The possible mechanism include 
 
 
 Contribution of Hepatitis C Virus and NODAT  (32) 
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INSULIN RESISTANCE :  
 This is the predominant pathogenic mechanism in causing NODAT. 
Hepatitis c virus causes diminished signalling through insulin receptor . this 
has been proven from biopsy specimens taken from liver of hepatitis c virus 
positive patients(33). 
 
DECREASED GLUCOSE UPTAKE BY LIVER 
 Hepatitis c virus core protein suppresses insulin mediated glucose 
uptake by the liver. The evidence comes from studies with hepatoma cells of 
human (34).  
 
DECREASED INSULIN SECRETION 
 HEPATITIS C VIRUS  PANCREATIC BETA  ISLET CELL 
CYTOPATHY- studies have demonstrated staining of hepatitis c virus in 
pancreatic beta islet cells resulting in decreased insulin secretion on 
stimulation by glucose. 
 
 IMMUNE MEDIATED ( MOLECULAR MIMICRY) has been 
proposed but this has not been proven by any studies(35). 
 
DECREASED HEPATIC GLYCOGENESIS 
 The expression of hepatitis c virus polyprotein inhibits post receptor 
pathway of insulin , thereby inactivates glycogen synthase activity. This has 
been proven by studies with human hepatic cell line(36).  
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 The expression of insulin receptors and insulin receptor pathway is 
increased in Hepatitis c virus infected patients when compared with 
hepatitis c virus uninfected patients , but the downstream signalling through 
phosphoinositide-3 kinase was  decreased in liver cells of hepatitis c virus 
infected individuals. So, the defect is beyond the insulin receptor 
contributing to the  insulin resistance and impairment of the glucose 
metabolism (37). 
 
 The meta analysis by Fabrizi et al, has shown that the seropositivity 
of hepatitis c virus confers a 3.75 fold increased risk of NODAT in renal 
transplant recipients (38). 
 
 The presence of HCV infection was associated with 62 % increase in  
risk of insulin resistance. A 10 fold increase in HCV RNA levels was 
associated with 8% increased risk for insulin resistance. The study by 
Kamar et al has shown that when hepatitis c virus patients are treated with 
interferon before transplant , the risk of development of NODAT is 
decreased (39).  
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IMPACT OF HEPATITIS C VIRUS ON RENAL 
TRANSPLANTATION 
 Meta analysis of eight  clinical trails   by  Fabrizi et al, out of which 
six were cohort studies and two were controlled studies comparing the 
outcomes of renal transplantation among hepatitis c virus positive  and 
hepatitis C virus negative recipients , reveal that adjusted relative risk of 
mortality was 1.79 with a confidence interval of 1.57 -2.03 in  hepatitis c 
virus positive recipients. This increased mortality is due to increased 
frequency of hepatocellular carcinoma and liver cirrhosis. There is an 
adjusted relative risk of graft loss  of 1.56 with a confidence interval of 1.35 
-1.80.This increased graft loss is due to increased occurrence of de novo 
immune mediated glomerular lesions, especially type I membrano 
proliferative glomerulonephritis post transplant (40). 
 
 The study by Rostami et al, analysed 18 observational studies , out of 
which 16 were retrospective cohort studies and 2 were clinical trials. In this 
study , the  combined hazard ratio for mortality of hepatitis c virus positive 
recipients compared to hepatitis c virus negative recipients was 1.69 times 
(1.33-1.97, p<0.0001)  and graft loss was 1.56 fold (1.22-2.004) (41). 
 
 The study by Jose Mario Morales et al, comparing the various clinical 
outcomes of hepatitis C virus infected renal transplant recipients and 
hepatitis c virus non infected renal transplanted recipients. This study 
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revealed that 4 year survival of the graft in HCV infected recipients was 
89.5% and HCV uninfected recipients was 94.4% , p <0.005. The survival 
of the patient in hepatitis infected recipients was 94.5% and HCV 
uninfected recipients was 96.6%, p<0.05. The incidence of acute rejection, 
severe proteinuria,  de novo glomerular disease was high in HCV infected 
renal transplanted recipients(42). 
 
 The study by S K Agarwal et al, compared  hepatitis C virus infected 
and hepatitis C virus .The follow up period was 30 months. During this 
follow up, the patient survival was 72% in hepatitis C virus infected group 
and 66% in hepatitis C virus uninfected group (statistically not significant). 
The allograft survival was 72%  in hepatitis C virus infected group and 66% 
in hepatitis C virus infected group and 66% in hepatitis C virus uninfected 
group  (statistically not significant) (43). 
 
 The incidence of acute rejection in HCV positive recipients was 
32.5% , in HCV negative recipients was 27.3%. (44) 
 
 Studies by Morales et al and Rao et al , have shown that hepatitis c 
virus positive patients have frequent blood stream infections like 
cytomegalovirus and sepsis. (45),(46) 
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RESULTS 
 
 A total of 266 patients underwent renal transplantation between 
2010 and 2013.  Three patients were detected hepatitis C virus 
infection after transplantation . These  three  patients were excluded from 
the study.  Out of the 263 patients, 28 recipients who  had hepatitis C 
virus infection before transplant were included in the study, the clinically 
significant outcomes  like acute rejection, NODAT, sepsis, cytomegalo 
virus infection , interstitial fibrosis and tubular atrophy (IFTA) were 
compared with 235 recipients  whose serology were  negative for 
hepatitis C virus.  
 
 Retrospective and prospective study of transplant   profile of 28 
recipients who had hepatitis c virus before transplant were studied in detail, 
the results are summarised as : 
 
• The mean duration of follow up was 23 months. 
• Of  the 28  recipients , 19  were males  with male: female ratio of 
2.1:1. 
• Mean age of the study population was 34 years(14-45 years). 
• Live related donor transplant was done in 23 patients (82%). 
• Deceased donor transplant was done in 5 patients (18%) . 
• Elevation of liver enzymes was present in 4 patients(14 %).  
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• Hepatitis  C virus RNA was detectable in 5 patients  (18%) . 
•  Out of 28 patients, only  one patient (3.5%) received interferon for 
six months before transplant. 
•  All the patients were started on triple immunosuppression of 
prednisolone, cyclosporine and mycophenoloate mofetil.   
•   Out of the 5 deceased transplant recipients , 3(60%) were given 
induction agents with basiliximab.  
• Delayed graft function was present in 11(39%) patients.  
• Acute cellular rejection was present in 8 patients (26%)  and  were 
treated with pulse methyl prednisolone. 
• New onset of diabetes mellitus after transplant (NODAT) was present 
in  16 patients (57%). All patients developed NODAT within 3 
months.  
• Sepsis (clinical evidence of sepsis and microorganism demonstrated 
by blood culture or urine culture) occurred in 17 recipients (61%). 
• Cytomegalovirus infection was present in 11 recipients (39%). 
• Invasive fungal infection was present in 7 recipients (25%).Biopsy  
done in 19 recipients (68%) revealed, 
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Findings Number 
Acute tubular injury 7 
Acute cellular rejection 8 
Calcineurin inhibitor toxicity 7 
Interstitial fibrosis and tubular atrophy 9 
Thrombotic microangiopathy 1 
Transplant glomerulopathy 1 
Focal segmental glomerulosclerosis 1 
 
 Post transplant worsening of liver function was present in 5 (18%) 
recipients, 4  (14%) among them had elevation in  HCV RNA level .  
 
 Liver biopsy was done in 1 recipient (3.5%)  findings were: 
 CHRONIC HEPATITIS: Ishak modified hepatitis index  
inflammatory scale  (HAI) 4/118, fibrosis 2/6. 
 
 The clinical outcome of the one recipient (3.5%) treated with 
interferon pretransplant was better, there was no progression of liver 
disease. 
 
 Two  recipients (7%) developed graft artery thrombosis in the post 
operative period and graft nephrectomy was done to both recipients and 
became dialysis dependent. 
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      Interferon was given to one post graft nephrectomy recipient (3.5%)  
who developed  worsening of liver function  and massive elevation  of HCV 
RNA titers.  
 
      All recipients underwent   alpha seum feto protein  test yearly , no 
recipient showed clinical or biochemical evidence of  hepatocellular 
carcinoma.  
 
      Routine urine examination revealed protienuria in one patient (3.5%), 
for whom biopsy was done which revealed focal segmental 
glomerulosclerosis. 
 
      One recipient (3.5%) expired due to sepsis 20 days following transplant,   
one year patient survival rate in HCV positive recipients was 96.43%.  
 
     On follow up, 3 recipients became dialysis dependent (10.71%).  Normal 
graft function was present 15 recipients (54%), with mean s.creatitine 
of0.9mg/dl. 
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GENDER 
 
 
Gender 
Distribution HCV+ % HCV- % 
Male 19 67.86 161 68.51 
Female 9 32.14 74 31.49 
Total 28 100 235 100 
P value 0.9439 
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AGE 
 
 
Age HCV+ % HCV- % 
10 to 20 3 10.71 32 13.63 
21 to 30 10 35.71 64 27.27 
31 to 40 8 28.57 96 40.90 
41 to 50 6 21.43 43 18.20 
51 to 60 1 3.57 0 0.00 
Total 28 100 235 100 
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NODAT 
 
 
NODAT HCV+ % HCV- % 
NODAT+ 16 57.14 82 34.89 
NODAT- 12 42.86 153 65.11 
Total 28 100 235 100 
Hazard Ratio 2.4878 
95% CI 1.1233 to 5.5097 
RR 2.2449 
P value 0.0247* 
 
 The incidence of NODAT in HCV positive recipients  was  57.14%, 
in HCV negative recipients  was 34.89%. This difference was statistically 
significant (p = 0.0247). 
 
 The HCV positive recipients has 2.24 fold increased risk of 
developing NODAT ( H.R. 2.4878 with CI of 1.12 to 5.5 ).  
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SEPSIS 
 
 
SEPSIS HCV+ % HCV- % 
SEPSIS+ 17 60.71 88 37.45 
SEPSIS- 11 39.29 147 62.55 
Total 28 100 235 100 
Hazard 
Ratio 2.5816 
95% CI 1.1564 to 5.7634 
RR 2.3255 
P value 0.0206* 
  
 The incidence of sepsis in HCV positive recipients was 60.71%,  in  
HCV negative recipients was 37.45%. This difference was statistically 
significant (p=0.026).  
 
 The HCV positive recipients were 2.32 fold higher risk of developing 
sepsis (2.58 with CI 1.15 TO 5.76). 
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IFTA 
 
 
 
IFTA HCV+ % HCV- % 
IFTA+ 9 32.14 68 28.94 
IFTA- 19 67.86 167 71.06 
Total 28 100 235 100 
Hazard Ratio 1.1633 
95% CI 0.5013 to 2.6994 
RR 1.1442 
P value 0.7247 
 
 The incidence of IFTA in HCV positive recipients were 32.14%, in 
HCV negative recipients were 28.94%. This incidence was not statistically 
significant, p=0.7247. 
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 CMV INFECTION 
 
 
 
CMV HCV+ % HCV- % 
CMV+ 11 39.29 44 18.72 
CMV- 17 60.71 191 81.28 
Total 28 100 235 100 
Hazard 
Ratio 2.8088 
95% CI 1.2294 to 6.4172 
RR 2.7723 
P value 0.0143* 
 
 The incidence of Cytomegalovirus in HCV positive group 39.29%, in 
HCV negative group was 18.72%. This difference was statistically 
significant, p= 0.0148. The HCV positive group had 2.8 fold of developing 
CMV infection when compared with HCV negative group, with hazard ratio 
of 2.8088 with C.I. of 1.2294 to 6.4172. 
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FUNGAL INFECTION 
 
 
 
Fungal Infection HCV+ % HCV- % 
FUNGAL+ 7 25.00 98 41.70 
FUNGAL- 21 75.00 137 58.30 
Total 28 100 235 100 
Hazard Ratio 0.4660 
95% CI 0.1906 to 1.1391 
RR 0.5016 
P value 0.0941 
 
 The incidence of fungal infection in HCV positive recipients was 
25%, in HCV negative recipients was 41.7%, this difference was not 
statistically not significant, p=0.0941. 
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ACUTE REJECTION 
 
 
Acute Rejection HCV+ % HCV- % 
Acute Rejection+ 8 28.57 68 28.94 
Acute Rejection- 20 71.43 167 71.06 
Total 28 100 235 100 
Hazard Ratio 0.9824 
95% CI 0.4128 to 2.3379 
RR 0.9842 
P value 0.9679 
 
 The incidence of acute rejection in HCV positive recipients was 
28.57%, in HCV negative recipients was 28.575, this difference was 
statistically insignificant, p=0.9679. 
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MORTALITY 
 
 
 
MORTALITY HCV+ % HCV- % 
MORTALITY+ 1 3.57 32 13.62 
MORTALITY- 27 96.43 203 86.38 
Total 28 100 235 100 
Hazard Ratio 0.235 
95% CI 0.0308 to 1.17898 
RR 0.2581 
P value 0.1621 
 
 The incidence of mortality in HCV positive group  was  3.57% , in 
HCV negative recipients was 13.62%, this difference was statistically 
insignificant, p=0.1621.  
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GRAFT LOSS 
 
 
 
Graft Loss HCV
+ 
% HCV- % 
Graft Loss+ 2 7.14 9 3.83 
Graft Loss- 26 92.86 226 96.17 
Total 28 100 235 100 
Hazard Ratio 1.9316 
95% CI 0.3959 to 9.4255 
RR 1.7622 
P value 0.4156 
 
 The incidence of graft loss in HCV positive recipients was 7.14%, in 
HCV negative recipients was 3.83 %, this comparison was statistically 
insignificant, p=0.4156. 
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DIALYSIS DEPENDENCY 
 
 
 
Dialysis Dependency HCV+ % HCV- % 
Dialysis Dependency+ 3 10.71 18 7.66 
Dialysis Dependency- 25 89.29 217 92.34 
Total 28 100 235 100 
Hazard Ratio 1.4467 
95% CI 0.3989 to 5.2579 
RR 1.3829 
P value 0.5749 
  
 The incidence of dialysis dependency in HCV positive recipients was 
10.7%, in HCV negative recipients was 7.665, this comparsion was 
statistically insignificant ,p= 0.5749.  
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DISCUSSION 
 
 In our study ,the mortality rate  in  HCV positive  recipients was 
3.57% and adjusted relative risks for mortality was 0.235 with C.I. of 0.03 
to 0.18. Hepatitis C virus positivity did not confer  any increased risk of 
mortality and graft loss  when compared to hepatitis C virus negative 
recipients. 
 
 Meta analysis of eight  clinical trials   by  Fabrizi et al, comparing the 
outcomes of renal transplantation among hepatitis C virus positive  and 
hepatitis c virus negative recipients , revealed that adjusted relative risk of 
mortality was 1.79  with a confidence interval of 1.57 -2.03 in  hepatitis C 
virus positive recipients. There was an adjusted relative risk of graft loss of 
1.56 with a confidence interval of 1.35 -1.80 (40). 
 
 Rostami et al, reviewed  18 observational studies. They concluded 
that the  combined hazard ratio for mortality of hepatitis C virus positive 
recipients compared to  hepatitis  C  virus negative recipients was 1.69 times 
(1.33-1.97, p<0.0001)  and graft loss was 1.56 fold (1.22-2.004). (41) 
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 In another study by S K Agarwal, hepatitis  C  positive recipients and 
hepatitis  C  virus negative recipients were  followed  up for a  period of 30 
months. The patient survival and graft survival was similar (43). 
 
 In our study, the  hepatitis C virus  positive recipients had  2.24 fold 
increased risk of developing NODAT( H.R. 2.4878 with CI of 1.12 to 5.5 ). 
The meta analysis by Fabrizi et al , has shown that the seropositivity of 
hepatitis C virus confers a 3.75 fold increased risk of NODAT in renal 
transplant recipients(40).   
 
  The  hepatitis  C virus   positive  recipients had  2.32 fold higher risk 
of developing sepsis. The   hepatitis C  virus    positive recipients   had 2.8 
fold of developing  cytomegalovirus infection when compared  with  
hepatitis C virus negative recipients. 
 
          Rao  K et al, analyzed the incidence of sepsis and cytomegalovirus 
infection among hepatitis C positive  recipients and hepatitis C negative 
recipients. They have  shown that hepatitis C positive  recipients had a 1.8 
fold  increase  in incidence   of sepsis and cytomegalovirus infection  when 
compared to negative  recipients (46).  
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       Studies   by  Morales  et  al and  Rao  et al , have shown that hepatitis C 
virus positive patients have frequent blood stream infections like 
cytomegalovirus and sepsis (45) (46).  
 
 According to the study   by  Morales et al, the incidence of acute 
rejection  in HCV positive recipients was 32.5%, in HCV negative 
recipients was 27.3%  (44). In our study the incidence of acute rejection in 
HCV positive  and negative  recipients was similar. 
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CONCLUSION 
 
 The short term patient and graft survival of HCV positive recipients 
was better.  
 
 There was  high incidence of NODAT in HCV positive recipients, 
and occurrence of  NODAT was  within 3 months after transplant. 
 
 The incidence of sepsis and cytomegalovirus in HCV positive 
recipients was higher, it is better to keep minimal level of 
immunosupression. 
 
 The incidence of acute rejection, interstitial fibrosis, fungal infection 
and graft survival in HCV positive recipients was not statistically significant 
from HCV negative recipients. 
 
 The short duration of follow up is a main limitation of the study. 
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PROFORMA 
 
Name:                                   Age:                            Sex:                     NC No.: 
Occupation: 
 
PRE TRANSPLANT PROFILE: 
   1.Native kidney disease 
      2. Duration of Chronic Kidney Disease 
    3.Duration of dialysis prior to transplant 
   4..History of blood transfusion 
   5. History of Jaundice 
   6.History of Cardiovascular disease 
 7.Viral Serology   - HCV /HBV /HIV 
                     HCV —ELISA ----QUALITATIVE PCR   
   8.HCV RNA LOAD   ----Initial 
                                       ----Final   
 9.Treated with interferon --    yes/no 
                If yes -dose and duration 
 10.LFT 
          S.bilirubin(d) 
               (indirect) 
            S. protein (t) 
            S.albumin 
            S.globulin  
                 SGOT 
                SGPT 
                  ALP 
TRANSPLANT PROFILE : 
 1.  Date of transplant 
 2.  Donor  -    Live/Cadaver 
              Donor     age          sex 
           3.  INDUCTION AGENT 
 4.  IMMUNOSUPPRESION 
   5.    ACUTE REJECTION     
 6.     ANTI REJECTION THERAPY   
 7.       GRAFT DYSFUNCTION-  early/ late                                                       
 8.  NODAT 
 9. POST TRANSPLANT   CHRONIC LIVER DISEASE 
 10. POST TRANSPLANT HCV RNA STATUS 
 11. PROTEINURIA 
 12.  POST TRANSPLANT INFECTIONS 
   Blood C/S  
             Urine      C/S 
             Cytomegalovirus 
  Invasive  fungal infections 
         Others 
       13. THROMBOTIC  MICROANGIOPATHY(biopsy proven) 
      14. FIBROSING  CHOLESTASIS 
      15. CRYOGLOBULINEMIA 
 16. POST TRANSPLANT INTERFERON  
      17. LFT  
           S.bilirubin (d) 
                (indirect) 
           S. protein (t) 
           S.albumin 
           S.globulin  
                 SGOT 
                 SGPT 
                   ALP 
 18. RENAL BIOPSY 
  19. LIVER BIOPSY 
 20. DEATH 
     Cardiovascular 
      Hepatic failure 
     Infections 
       Cancer 
     Other 
INVESTIGATIONS: 
1. Urine analysis 
                  Protein  
                  Sugar 
                 Deposits 
                  P.C.R.     
          2. Hemogram 
                   Hemoglobulin (gm/dl) 
                 Total  count 
                  Differential count 
                   E.S.R. 
 3. Peripheral Smear 
 4. Blood  Urea (mg/dl)- 
                         S.Creatinine(mg/dl)- 
                        S.Electrolytes (mEq/l)- 
 5. Blood sugar (mg/dl) 
  
 6. LFT 
           S.BILIRUBIN 
                        Direct 
                     Indirect 
                       SGOT 
                       SGPT 
            S.PROTEINS 
                ALBUMIN 
                 GLOBULIN 
 7. PT/INR 
      8. VIRAL SEROLOGY  - HCV/HBV/HIV 
 9. HCV RNA LOAD 
 10. CHEST X RAY 
 11. ULTRASOUND ABDOMEN 
 12.UPPER GASTRO INTESTINAL ENDO SCOPY  
 13.RENAL BIOPSY 
 14. LIVER BIOPSY 
 
FINAL DIAGNOSIS 
  
MASTER CHART 
 
  
 GLOSSARY 
CMV    - Cytomegalovirus                                              
UTI   - Urinary Tract Infection                                   
                        HBV             - Hepatitis B virus 
HCV              - Hepatitis C virus 
PCR                - Polymerase Chain Reaction 
TAC           - Tacrolimus 
MMF        - Mycophenolate Mofetil 
PDN             - Prednisolone 
AZA               - Azathioprine 
CYC             - Cyclosporine 
CNI              - Calcineurin Inhibitor 
GDF             - Graft Dysfunction 
DGF              - Delayed Graft Function 
ATN             -  Acute Tubular Necrosis 
NODAT       -  New Onset of Diabetes Mellitus 
ART             - Antirejection therapy 
IFN             - Interferon 
ACR   - Acute  Cellular Rejection 
 
  
KEY TO MASTER CHART 
A.C.R.   - Acute Cellular Rejection 
Bx   - Biopsy 
C/S   - Culture And Sensitivity 
CGN    - Chronic Glomerulonephritis 
Cyclo/MMF  - Cyclosporine/Mycophenoloate Mofeti; 
D/W S.Cr.,CREAT  - Discharge with S. Creatitine 
Dial.Dependency - Dialysis Dependency 
DOT       - Date of Transplant 
Du, Dur,  - Duration 
F     -  Female 
F.U        - Follow Up Duration 
FUN    - Fungal 
GDF         -     Graft Dysfunction 
H.Z     - Herpes Zoster 
HCV      - hepatitis C virus 
HES       - Herpes Simplex                      
Immunosupp.   - Immunosuppressants 
M      -  Month 
M    -  Male 
Nephrect.  - Nephrectomy 
NKD    - Native Kidney Disease Not Known 
NO.                - Number 
OT   -  SGOT (Serum Glutamic Oxaloacetic Transminase) 
PT    - SGPT (Serum Glutamic Pyruvic Transaminase) 
RNA   -  Ribonucleic Acid 
TMA    - Thrombotic Microangiopathy 
TOX.    - Toxicity 
Y ,Yr.   - Year 
